Abstract
Abstract Objective To describe the changing patterns in the use of the various classes of antidiabetic drugs in a cohort of patients newly treated for diabetes from 2008 to 2015 on the basis of comprehensive health insurance data. Methods General scheme beneficiaries 45 years and older were identified in the French National Health Data System (SNDS) as newly treated when antidiabetic drugs were dispensed on at least 3 different dates in 2008 and at least once during the last 4 months of 2008, but were dispensed less than 3 times in 2006-2007. Treatment regimens for the last 4 months of each year were defined for this cohort. Results 158,000 people (53% men, mean age 62 years) initiated antidiabetic drug therapy in 2008: monotherapy (without insulin): 74%, dual therapy: 17%, treatment with 3 or more drugs: 3%, and insulin therapy: 7%. The proportion of patients taking monotherapy decreased by 13 percentage points during the second year and only 32% of the cohort was treated by monotherapy 8 years after starting treatment. The proportions of patients taking dual therapy increased by 4 percentage points (21% in 2015), triple therapy increased by 8 percentage points (11%), a combination of insulin+other antidiabetics increased by 4 percentage points (7%) and insulin alone remained stable (4%). At the last quarter of 2015, 12% of patients did not receive any antidiabetic drugs and 13% had died. The creation of a cohort of diabetic patients newly treated in 2013 demonstrated changing prescribing practices: a lower proportion of monotherapy in the first year of treatment, but a growing use of metformin. Conclusions Treatment was intensified during the first 8 years for one half of the cohort. The maximal dosage of Metformin is not used before introducing a second antidiabetic in 1 case in 2. Insufficient use of Metformin, in general and in terms of dosage, was observed, although this use is improving. Key messages Initiation of antidiabetic drug therapy in people 45 years and older consisted of monotherapy in 3/4 of cases in 2008. Insufficient use of Metformin, in general and in terms of dosage, was observed, although this use is improving.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.